A new study has found that lutein, a nutrient in brightly colored fruit and vegetables, can reduce inflammation in patients with coronary artery disease.
Carried out by researchers at Linkoping University, Sweden, the study looked at the levels of six of the most common carotenoids in blood from 193 patients with coronary artery disease.
“A considerable number of patients who have experienced myocardial infarction still have low-level chronic inflammation in the body, even after receiving effective treatment with revascularisation, drugs and lifestyle changes.
“We know that chronic inflammation is associated with a poorer prognosis,” explained study leader Lena Jonasson.
Carotenoids are the mainly red, orange, and yellow pigments which give the bright colour to plants, vegetables, and fruits, such as ripe tomatoes, or dark-green leafy vegetables such as spinach.
Previous research has already suggested that carotenoids, such as the more well known beta-carotene and lycopene, could be linked with inflammation, which is a key factor in many types of coronary artery disease, such as myocardial infarction and angina.
To look at their potential anti-inflammatory effect, the team also measured the level of inflammation in the blood using the inflammatory marker interleukin-6, IL-6.
They discovered that lutein was the only carotenoid whose level correlated with IL-6, finding that the higher the level of lutein in the blood, the lower the level of IL-6.
The researchers now plan to research further to see whether whether increased consumption of foods rich in lutein has a positive effect on the immune system in patients with coronary artery disease.
The findings can be found published online in the journal Atherosclerosis.
Read more here.
NEVADA HEART AND VASCULAR CENTER ANNOUNCES PARTNERSHIP WITH DESERT SPRINGS HOSPITAL OFFERING FIRST-OF-ITS-KIND NATURALLY DISSOLVING HEART STENT FOR PATIENTS WITH CORONARY ARTERY DISEASE
Recently approved by FDA, Absorb bioresorbable vascular scaffold opens
clogged arteries to restore blood flow, then gradually dissolves in the bodyreducing the risk of future blockages that can occur with metal stents
Las Vegas, NV (September 28, 2016) On Tuesday, September 27, Nevada Heart and Vascular Centers Board Certified Interventional Cardiologist Rafael Valencia M.D., F.A.C.C., implanted a patient with the world’s first FDA-approved dissolving heart stent. The Absorb bioresorbable vascular scaffold is a major advance in the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide despite decades of therapeutic advances.
It was a privilege to be given the opportunity to be part of the first interventional cardiology team in Southern Nevada to implant the new fully bioresorbable Absorb coronary stent. Today is a great example of how our medical community, in particular the physicians of Nevada Heart and Vascular Center and the dedicated cardiovascular staff at Desert Springs Hospital, in partnership with leading health industry companies can deliver innovative and state of the art cardiac care to patients in Southern Nevada. This novel technology promises to be a great addition to the treatment options we can offer our patients to improve their health and well being. The physicians of Nevada Heart and Vascular Center are excited to be able to deliver this innovative therapy to patients throughout the Las Vegas valley, Said Dr. Valencia.
About Nevada Heart and Vascular Center
Nevada Heart and Vascular Center has twenty-two, full-time, board certified cardiologists with seven convenient locations throughout Southern Nevada. For more information about Nevada Heart and Vascular Center or to see if you could be a candidate for this procedure please visit www.NevadaHeart.com or contact our office at 702-CARDIAC (227-3422)